No patient diagnosed with thrombosis in our study had been treated with daratumumab, an anti-CD138 therapy that is now licensed for induction therapy for MM as well as for the relapsed setting by the European Medicines Agency (EMA). The gene discussed is SDC1; the disease is deep vein thrombosis.